An Antiviral Formulation Clevira Received Government of India Regulatory Approval
News Desk, News Nation 360 : India recently witnessed a severe pandemic wave including West Bengal that overwhelmed the healthcare system. It is in this context, supportive treatment can help in reducing the need for hospitalization among patients suffering from mild to moderate Covid-19 significantly. Even one patient less in the ICU means a lot during such crises, this would ensure better allotment of resources and medical attention for the needy. A clinical trial was conducted on 100 people in May-June 2020 and the results were promising. During the 30 days trial, conducted at Government Medical College, Omandurar Government Estate Chennai, after approval from the Tamil Nadu government, the selected 100 participants were randomized into 2 groups with 50 patients in each: the control group comprised of patients diagnosed with SARS-CoV-2 infection received standard care treatment as per hospital regulation as well as the WHO/ICMR guidelines. The test group patients with SARS-CoV-2 infection received, along with standard care treatment (as per hospital regulation and the WHO/ICMR guidelines) Clevira tablets twice daily orally after food for 14 days. It was found that Clevira significantly reduced the time taken for clinical recovery, which was noted in terms of reduction in pyrexia or body pain, normalisation of the respiratory rate ( less than 24/minute), improvement in oxygen saturation level ( more than 94%), etc. Explaining the benefits and uses of Clevira, C Arther Paul, Manager International Business, Apex Laboratories, said that the antiviral drug increases the WBC, Platelet and Lymphocyte counts significantly within the normal range apart from reducing the Viral load, hence the recovery from all signs and symptoms is much faster. Significant reduction in Erythrocyte Sedimentation Rate (ESR) is evidence that the drug elicits anti-inflammatory properties. Clevira is proven effective as an Analgesic, Antipyretic and reversal of thrombocytopenia. It is absolutely safe for people with liver or kidney ailments and can be safely co-administered with other drugs. It can also be used as a prophylactic treatment for primary contacts of COVID19 positive patients and frontline healthcare workers. The drug is recommended for all age groups from the age of 2 years. Besides, on treatment with Clevira, 86% of patients turned out to be COVID19 RT-PCR test negative on day 5 and 100% of patients turned out to be COVID19 RT-PCR test negative on day 10. Clinical improvement of signs and symptoms of COVID19 was achieved in 4.1 days.
Pic : Krishnendu Kundu
Report : Anustup Kundu